SangStat Thymoglobulin Distribution In Canada
California, USA-based SangStat has initiated distribution in Canada of Thymoglobulin, a polyclonal antibody for the treatment of organ rejection in transplant patients. The company filed for marketing approval in Canada last year (Marketletter September 26, 1994) and will distribute the drug under the Emergency Drug Release program prior to potential market approval.
SangStat took over distribution of Thymoglobulin in Canada on January 1 from Pasteur Merieux Serums et Vaccines subsidiary Connaught Labs, and has licensed exclusive commercial rights for the drug from PMSV for the USA and Canada. Although this marks the first revenues from a SangStat drug candidate in North America, the sales will obviously be limited until market approval is gained.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze